Ardent Health's second quarter arrived with a calendar trap the headlines couldn't see: the year-ago quarter had captured two quarters' worth of New Mexico Medicaid directed-payment revenue because the program's renewal had slipped into 2025. Strip that out and the quarter's story is two narratives running at once. Total revenue fell 1.4% to $1.62 billion, admissions slipped 1.0%, and inpatient surgeries dropped 7.5% - and Adjusted EBITDA fell 32% to $115 million. Dave Caspers, who moved up from Chief Operating Officer to President and Chief Executive Officer during the quarter, called the volume miss head-on: "lower surgeries and admissions," and "earnings pressure." At the same time, the company reaffirmed full-year 2026 guidance of $6.4–$6.7 billion of revenue and $485–$535 million of Adjusted EBITDA, raised the target on its IMPACT cost program from $55 million to at least $70 million of 2026 savings, and delivered Q2 operating cash flow of $197 million - up 67% year over year. The headline said miss; the ledgers said hold.
The four numbers that matter most sit in tension. Q2 Adjusted EBITDA of $115 million ran 32% below a year ago, but the year-ago figure carried roughly $58 million of one-time NM Medicaid revenue that did not repeat. Cash and cash equivalents of $724 million plus $268 million of ABL availability gave $992 million of liquidity at quarter-end. Net leverage of 0.8x and lease-adjusted net leverage of 2.6x are the cleanest balance-sheet metrics in the company's history. The market, however, was unimpressed: shares closed at $11.02 on August 13, near a 52-week low of $7.71 hit in early June after an intra-quarter volume update, and roughly 29% below the 52-week high of $15.48 reached in October 2025. The market is pricing the company as if the soft quarter were the new run-rate, not a Medicaid timing artifact inside a reaffirmed guide.
Three sub-stories live underneath. A new CEO's first full quarter, with Caspers explicitly framing the work as staffing, contracting, capital allocation, standardization, and accountability - operational sharpening, not strategy reset. A real-estate-lease model in which 12 of 30 hospitals are leased from Ventas and Medical Properties Trust under long-term master leases, with management viewing REIT rent as closer to interest expense than operating rent, and the valuation lens as Adjusted EBITDAR rather than Adjusted EBITDA. An active capital-return program: a $50 million repurchase authorization from November 2025, with $34 million still available after $13 million of Q2 buybacks, the first repurchases under the new program. The investment question is not whether the quarter was soft. It was. The question is whether the volume mix is recovering, the cost program is durable, and management is allocating capital with discipline. The company says yes on all three. The market has not yet agreed.